novo nordisk glp-1 patent litigation Ozempic, Wegovy and Rybelsus: The patents behind Nordisk's weight-loss drugs The Heavy Price of GLP-1

Thirdly, GLP-1 agonists slow gastric emptying, leading to a delayed absorption of nutrients and a prolonged feeling of fullness, which can contribute to reduced food intake and weight loss

Supply issues could ease but won't go away The supply problems plaguing Wegovy, Ozempic and Mounjaro are likely "the biggest thing" investors will watch next year, Guggenheim analyst Seamus Fernandez told CNBC

00:00:22 Narrator She walks through how it compares to injections, what patients need to know about administration, and when switching dosage forms makes sense, in an excerpt from our popular Pharmacy Essential Updates webinar series

Once the broader market realized this, demand started to rise from individuals who may not be candidates for the drug